[Congressional Record (Bound Edition), Volume 154 (2008), Part 12]
[Extensions of Remarks]
[Page 16544]
[From the U.S. Government Publishing Office, www.gpo.gov]




                   THE AMERICAN SOCIETY OF HEMATOLOGY

                                 ______
                                 

                       HON. JESSE L. JACKSON, JR.

                              of illinois

                    in the house of representatives

                        Thursday, July 24, 2008

  Mr. JACKSON of Illinois. Madam Speaker, I rise today to commend the 
American Society of Hematology (ASH) on its 50th anniversary. I also 
want to thank hematologists for their significant contributions to the 
research, treatment, and advocacy of sickle cell disease and other 
blood and bone marrow disorders.
  Sickle Cell disease affects between 50,000 and 100,000 individuals in 
this country. In addition, almost 2,000 babies are born with sickle 
cell disease each year. While researchers make progress with 
treatments, patients continue to suffer from debilitating pain, 
frequent infections, anemia, and vision problems. Sickle cell disease 
also can lead to serious complications such as blood clots, organ 
failure, and strokes.
  Undoubtedly, hematologists have helped lead the way in the 
development of new therapies and treatments for sickle cell disease. As 
a result of their work and advocacy, today's neonatal screening program 
has improved the overall health and survival of patients. In 1998, 
transcranial screening allowed doctors to identify sickle cell patients 
at risk for stroke and treat them with blood transfusions. 
Hematologists also have been responsible for pioneering the use of 
hydroxyurea in the successful treatment of the disease.
  Moreover, ASH has been a leader in sickle cell advocacy by seeking 
additional funding for the Federal Government's sickle cell programs as 
well as helping Federal agencies identify major scientific 
opportunities in basic and clinical research of the disease. ASH was 
one of the leading organizations working with Congress on legislation 
to create the Sickle Cell Disease Treatment Demonstration Program--a 
federally funded program designed to improve and expand patient and 
provider education and the continuity and coordination of care for 
individuals with the disease. In fact, ASH worked diligently with 
congressional leaders to fund this program through August, 2010.
  I look forward to continuing to work with ASH and its members to 
pursue the common goal of expanding research and providing excellent 
care for patients with sickle cell disease.

                          ____________________